PE Rabbit anti-Mouse CD161c/NK1.1 Monoclonal Antibody for FC - P27814

Core Product Specifications and Parameters

Biological Background: CD161c/NK1.1 Function and Localization

• Killer cell lectin-like receptor subfamily B member 1C (KLRB1C), also known as NKR-P1C, CD161c, or NK1.1, is a type II transmembrane glycoprotein belonging to the C-type lectin family.
• It acts as a stimulatory receptor on natural killer (NK) cells, where crosslinking induces Ca²⁺ mobilization and interferon-gamma production, enhancing cytotoxicity.
• The receptor is encoded by the Klrb1c gene in mice and is a member of the NKR-P1 gene family, which includes both activating and inhibitory isoforms.
• Subcellularly, KLRB1C is localized to the plasma membrane as a single-pass membrane protein with a signal-anchor and a transmembrane helix.
• Post-translational modifications include disulfide bond formation and glycosylation, contributing to its structure and function.
• Alternative splicing produces multiple transcript variants, potentially modulating receptor activity.
• It is predominantly expressed in natural killer cells, serving as a key marker for NK cell subsets in mice.

Experimental Guidance and Technical Tips

• This antibody is designed for flow cytometry; appropriate fluorophore-conjugated secondary antibodies or direct PE conjugation enables sensitive detection.
• The immunogen corresponds to the extracellular domain (aa 67-223) of mouse CD161c/NK1.1, ensuring specificity for the native receptor on NK cells.
• For optimal staining, titrate the antibody in the relevant mouse strain and cell type to determine the optimal working concentration.
• Consider co-staining with other NK cell markers (e.g., CD3, CD49b) to define NK cell subpopulations.
• Confirm expression by analyzing mouse spleen or lymph node cells as positive controls.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a single-source partner for IVD manufacturers, providing validated antibody pairs, optimized monoclonal antibodies, and bulk ancillary reagents. Our portfolio includes reliable anti-NK1.1 antibody solutions to support immunophenotyping and immuno-oncology assay development. We leverage a robust supply chain to source rare-target raw materials, bridging the gap from concept to clinic.